Preclinical data show the vectorized miRNA candidate achieved durable knockdown of SCN9A (NaV1.7), a genetically validated pain target historically difficult to modulate In non-human primates, ...
SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A ...
Imagine being unable to feel any pain at all. For a tiny handful of people, that is the reality — and medical researchers have now pinpointed the mutation that removes their ability to perceive ...
Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. We’re ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results